Ikena Oncology, Inc. (IKNA) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
645 Summer Street
Boston, MA 02210
United States of America (the)
Phone
857 273 8343
Website
Sector
Healthcare
Industry
Biotechnology
Employees
10
First IPO Date
March 26, 2021
| Name | Title | Pay | Year Born |
| Mark Manfredi | President, Chief Executive Officer & Director | 868,194 | 1972 |
| Jotin Marango | Chief Operating Officer, Chief Financial Officer, Head of Corporate Development & Treasurer | 809,946 | 1980 |
| Bob Lally | Senior Vice President of Finance & Operations | 0 | N/A |
| David Damphousse | Senior Vice President of Clinical Development Operations | 0 | N/A |
| Jeffrey Ecsedy | Chief Development Officer | 0 | 1970 |
| Valdas Jurkauskas | Senior Vice President of Technical Operations | 0 | N/A |
| Rebecca Cohen | Senior Vice President of Investor Relations, Corporate Strategy & Communication | 0 | N/A |
Ikena Oncology, Inc. is a biopharmaceutical company specializing in precision oncology. Its primary objective is to create therapeutic agents specifically formulated for patient populations identified through biomarkers, thereby addressing significant unmet medical needs. The company's leading drug candidate is IK-930, an orally administered small molecule designed to inhibit the transcriptional enhanced associate domain (TEAD) transcription factor, a key component of the Hippo signaling pathway. Ikena is also progressing a portfolio of other investigational therapies, including: A small molecule inhibitor program targeting ERK5 within the RAS signaling pathway. IK-175, an oral compound that inhibits the aryl hydrocarbon receptor. IK-007, an orally delivered, selective antagonist of the EP4 receptor, which is being developed for the treatment of microsatellite stable colorectal cancer. Founded in 2016, the company is based in Boston, Massachusetts.